FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

Blood

Volumn 104, Issue 10, 2004, Pages 3038-3045

  Pardanani, Animesh ^a   Brockman, Stephanie R ^a   Paternoster, Sarah F ^a   Flynn, Heather C ^a   Ketterling, Rhett P ^a   Lasho, Terra L ^a   Ho, Ching Liang ^a   Li, Chin Yang ^a   Dewald, Gordon W ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HYDROXYUREA; IMATINIB; INTERFERON; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISONE;

ADULT; ARTICLE; BONE MARROW CELL; CELL INFILTRATION; COHORT ANALYSIS; EOSINOPHIL; EOSINOPHILIA; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE DELETION; GENE LOCUS; GENE MUTATION; GENE TRANSLOCATION; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAST CELL; MASTOCYTOSIS; PREVALENCE; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

EID: 8644263305     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-0787     Document Type: Article

References (14)

1. Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol. 2003;121:203-223.
2. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577-1578.
3. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
4. Pardanani AD, Elliott MA, Reeder TL, et al. Imatinib therapy for systemic mast cell disease. Lancet. 2003;362:535-536.
5. Pardanani AD, Reeder TL, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101:3391-3397.
6. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101: 4714-4716.
7. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
8. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood. 2003;102:3093-3096.
9. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumors: tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer (IARC) Press; 2001:291-300.
10. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
11. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487.
12. Pardanani A, Reeder TL, Kimlinger TK, et al. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res. 2003;27:739-742.
13. Escribano L, Diaz-Agustin B, Nunez R, Prados A, Rodriguez R, Orfao A. Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Appl Immunol. 2002;127:127-132.
14. Miranda RN, Esparza AR, Sambandam S, Medeiros LJ. Systemic mast cell disease presenting with peripheral blood eosinophilia. Hum Pathol. 1994;25:727-730.